![Matthew Ros](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Matthew Ros
Director/Board Member at
COGENT BIOSCIENCES, INC.
Net worth: 216 500 $ as of 31/05/2026
Profile
Matthew E.
Ros is currently an Independent Director at Cogent Biosciences, Inc. since 2019.
Former roles include Chief Executive Officer & Director at Fore Biotherapeutics, Inc. from 2022 to 2023; Senior Director at Bristol Myers Squibb Co. from 1990 to 2007; Senior Vice President-Commercial Operations at ARIAD Pharmaceuticals, Inc. from 2009 to 2010; Vice President & Head-Franchise at Genzyme Corp.
from 2012 to 2014; Associate Vice President at Sanofi from 2010 to 2012; COO, VP & Global Head-Oncology Business Unit at Sanofi from 2014 to 2016; Chief Financial Officer at Epizyme, Inc. in 2021; Trustee at Cancer Care, Inc.; and Chief Operating Officer at Verastem, Inc. in 2025.
Education includes an undergraduate degree from The State University of New York, conferred in 1988.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
VERASTEM, INC. 0.08% | 01/04/2025 | 50,000 ( 0.08% ) | 216 500 $ | 31/05/2026 |
| 13/04/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Matthew Ros active positions
| Companies | Position | Start |
|---|---|---|
| COGENT BIOSCIENCES, INC. | Director/Board Member | 26/07/2019 |
Former positions of Matthew Ros
| Companies | Position | End |
|---|---|---|
| VERASTEM, INC. | Chief Operating Officer | 15/12/2025 |
Fore Biotherapeutics, Inc.
 Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology company that specializes in cancer therapies | Chief Executive Officer | 01/08/2023 |
| EPIZYME, INC. | Director of Finance/CFO | 01/10/2021 |
| SANOFI | Chief Operating Officer | 01/05/2016 |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Corporate Officer/Principal | 01/12/2014 |
Training of Matthew Ros
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
96
1st degree connections
10
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes small-molecule drugs for the treatment of cancer | Health Technology |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Sanofi
 Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
Cogent Biosciences, Inc.
 Cogent Biosciences, Inc. BiotechnologyHealth Technology Discovers and develops new cellular immunotherapies for cancer | Health Technology |
Cancer Care, Inc.
 Cancer Care, Inc. Hospital/Nursing ManagementHealth Services Provides cancer treatment services | Health Services |
The State University of New York
 The State University of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Develops therapeutics for the treatment of patients with genetically defined cancers | Health Technology |
Verastem, Inc.
 Verastem, Inc. BiotechnologyHealth Technology Discovers and develops drugs | Health Technology |
Fore Biotherapeutics, Inc.
Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology company that specializes in cancer therapies | Health Technology |
- Stock Market
- Insiders
- Matthew Ros
